The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study.

In the real-world setting, vedolizumab is effective and well tolerated within the first 14 weeks of use in Korea. The proportion of patients experiencing clinical response and clinical remission at 6 and 14 weeks appeared to be largely consistent with that observed in real-world studies from other regions and populations.